- t1 28 days after allocation, t2a week 6 follow-up, t3b week 12 follow-up
- cChanges in liver disease severity, quality of life, and cost-effectiveness compared to standard care
- d(a) Source of referral, (b) re-enrolment after unplanned hospitalisation, (c) COVID-19, and (d) hepatic decompensation without ACLF